NO20082175L - Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser - Google Patents

Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser

Info

Publication number
NO20082175L
NO20082175L NO20082175A NO20082175A NO20082175L NO 20082175 L NO20082175 L NO 20082175L NO 20082175 A NO20082175 A NO 20082175A NO 20082175 A NO20082175 A NO 20082175A NO 20082175 L NO20082175 L NO 20082175L
Authority
NO
Norway
Prior art keywords
adenosine
extra
treatment
receptor antagonists
movement disorders
Prior art date
Application number
NO20082175A
Other languages
English (en)
Inventor
Michael Grzelak
John Hunter
Annamarie Pond
Geoffrey Varty
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20082175L publication Critical patent/NO20082175L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet en fremgangsmåte for behandling eller forebyggelse av ekstrapyramidalt syndrom (EPS), dystoni, hvileløse ben-syndrom (RLS) eller periodisk benbevegelse under søvn (PLMS) som omfatter administreringen av en adenosin A2a reseptorantagonist, alene eller i kombinasjon med andre midler som kan anvendes til behandling av EPS, dystoni, RLS eller PLMS; det er også krevet farmasøytiske preparater bestående av en adenosin A2a reseptorantagonist i kombinasjon med et antipsykotisk middel, et antikonvulsjonsmiddel, litium eller et opioid.
NO20082175A 2005-10-13 2008-05-09 Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser NO20082175L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/249,796 US20060128694A1 (en) 2002-12-19 2005-10-13 Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
PCT/US2006/039689 WO2007047293A1 (en) 2005-10-13 2006-10-11 Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Publications (1)

Publication Number Publication Date
NO20082175L true NO20082175L (no) 2008-07-11

Family

ID=37719335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082175A NO20082175L (no) 2005-10-13 2008-05-09 Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser

Country Status (11)

Country Link
US (1) US20060128694A1 (no)
EP (1) EP2001511A1 (no)
JP (1) JP2009511588A (no)
CN (1) CN101325974A (no)
AU (1) AU2006304102A1 (no)
BR (1) BRPI0617415A2 (no)
CA (1) CA2625859A1 (no)
NO (1) NO20082175L (no)
TW (1) TW200800263A (no)
WO (1) WO2007047293A1 (no)
ZA (1) ZA200803236B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP4778894B2 (ja) * 2003-06-10 2011-09-21 協和発酵キリン株式会社 不安障害の治療方法
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
ATE216584T1 (de) * 1992-07-08 2002-05-15 Kyowa Hakko Kogyo Kk Xanthine-derivate als antidepressiva
CN1646132A (zh) * 2002-01-28 2005-07-27 协和发酵工业株式会社 治疗运动疾病患者的方法
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ATE490775T1 (de) * 2002-12-19 2010-12-15 Schering Corp Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms
AU2004233334B2 (en) * 2003-04-23 2010-08-12 Merck Sharp & Dohme Corp. 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
KR20060135901A (ko) * 2004-04-21 2006-12-29 쉐링 코포레이션 피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]피리미딘아데노신 Ａ2ａ 수용체 길항제
WO2006009698A2 (en) * 2004-06-17 2006-01-26 The Regents Of The University Of California Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
DE602005014891D1 (de) * 2004-12-21 2009-07-23 Schering Corp PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS

Also Published As

Publication number Publication date
JP2009511588A (ja) 2009-03-19
AU2006304102A1 (en) 2007-04-26
US20060128694A1 (en) 2006-06-15
ZA200803236B (en) 2009-03-25
CA2625859A1 (en) 2007-04-26
BRPI0617415A2 (pt) 2011-07-26
EP2001511A1 (en) 2008-12-17
CN101325974A (zh) 2008-12-17
TW200800263A (en) 2008-01-01
WO2007047293A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
NO20053509L (no) Anvendelse av adenosin A2a -reseptorantagonister
NO20082175L (no) Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser
NO20076616L (no) 17beta-HSD1- og STS-inhibitorer
NO20064929L (no) Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
DK1578439T3 (da) Lavdosisfremgangsmåde til at behandle forstyrrelser, i hvilke TNF-alfa-aktiviteten er skadelig
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO2014028I2 (no) Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
NO20055957L (no) Metode for behandling av aterosklerose, dyslipidemi og beslektede tilstander, og farmasoytiske preparater
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20092612L (no) Forbindelser og metode for kinasemodulering og indikasjoner for dette
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
NO20081212L (no) Xantinderivater som selektive HM74A agonister
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application